MedTrace Logo

Blood Samples to Identify Biomarkers in Patients Treated With Cyclophosphamide After Donor Stem Cell Transplant

NCT04160390 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 72

Last updated 2025-07-28

No results posted yet for this study

Summary

This trial uses blood samples to understand how patients' bodies process and respond to a drug called cyclophosphamide given after a donor stem cell transplant. Identifying biomarkers (molecules that can indicate normal or abnormal processes) may help researchers develop a blood test that can be used to predict how well patients will process and respond to cyclophosphamide.

Conditions

  • Allogeneic Hematopoietic Stem Cell Transplant Recipient
  • Donor
  • Malignant Neoplasm

Interventions

OTHER

Biospecimen Collection-Blood

Undergo collection of blood

OTHER

Biospecimen Collection-Stool

Undergo collection of stool

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • City of Hope Medical Center

    lead OTHER

Principal Investigators

  • Jeannine S McCune · City of Hope Medical Center

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-11-13
Primary Completion
2027-04-24
Completion
2027-04-24

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04160390 on ClinicalTrials.gov